Company intelligence / Profile preview
XyloCor Therapeutics
King of Prussia, Pennsylvania, United Statesxylocor.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 2
01
Overview
XyloCor's lead product XC001 (encoberminogene rezmadenovec) has completed Phase 2 portion of its Phase 1/2 clinical trial (EXACT) with positive results. The 12-month data showed durable improvements across multiple efficacy measures, including continued improvement in total exercise duration and reductions in ischemic burden and ischemic symptoms. The treatment met both safety and efficacy objectives with no safety issues related to drug product or unexpected serious adverse events.[8][9]
- Therapeutic areas
- Cardiovascular
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on XyloCor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XyloCor Therapeutics.